# Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer

Source: https://onco.cc/trials/nct04322617/  
OnCo record `nct04322617` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of anlotinib in lung cancer, run by Hunan Province Tumor Hospital, now recruiting.

## Summary

Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer is a phase 2/3, interventional study registered as NCT04322617 by Hunan Province Tumor Hospital, with a registry enrolment figure of 1200 participants, started 2020-03-24 and due to reach its primary completion in 2028-03-24. Interventions recorded: Anlotinib plus the same Immune Checkpoint Inhibitors.; Anlotinib plus the new Immune Checkpoint Inhibitors.; Anlotinib. Conditions listed: Non-small Cell Lung Cancer. Primary outcome: Progression free survival time (PFS). Lung eligibility wording from the registry: "Histopathology or cytology confirmed lung cancer". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: ATHENA
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT04322617
- Phase: 2/3
- Setting: Anlotinib With or Without Immune Checkpoint Inhibitors in Standard Chemo-immunotherapy Failed Advanced Non-small Cell Lung Cancer
- Sponsor: Hunan Province Tumor Hospital
- Enrolled: 1200

## Sources

- ClinicalTrials.gov NCT04322617: https://clinicaltrials.gov/study/NCT04322617

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Anlotinib](https://onco.cc/drugs/anlotinib/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04322617.json